Published online Jun 28, 2017. doi: 10.3748/wjg.v23.i24.4437
Peer-review started: November 22, 2016
First decision: December 19, 2016
Revised: January 18, 2017
Accepted: March 15, 2017
Article in press: March 15, 2017
Published online: June 28, 2017
Processing time: 217 Days and 17.1 Hours
To verify the precision and accuracy of transglutaminase antibodies (TGA) assays across Mediterranean countries.
This study involved 8 referral centres for celiac disease (CD) in 7 Mediterranean countries. A central laboratory prepared 8 kits of 7 blinded and randomized serum samples, with a titrated amount of Human TGA IgA. Each sample was analysed three times on three different days, with each centre running a total of 21 tests. The results were included in a blindly coded report form, which was sent to the coordinator centre. The coordinator estimated the mean coefficient of Variation (CoVar = σ/μ), the mean accuracy (Accur = Vobserved - Vreal) and the mean percent variation (Var% = [(Vobserved - Vreal)/Vreal] × 100).
The analysis showed that 79.17% of the mean variation fell between -25% and +25% of the expected value, with the accuracy and precision progressively increasing with higher titres of TGA. From values 1.25 times greater than the normal cut-off, the measurements were highly reliable.
TGA estimation is a crucial step for the diagnosis of CD; given its accuracy and precision, clinicians could be confident in establishing a diagnosis.
Core tip: The “epidemic” of celiac disease (CD) across Mediterranean countries stimulated the need to standardize commonly used diagnostic tests. The titre of anti-transglutaminase antibodies has a strong relevance in the diagnosis of CD as defined by the ESPGHAN criteria; few studies, at the moment, estimated the variability of the main diagnostic tool for CD, in terms of accuracy and precision. Our study represents the first quality control work on this subject, with strong implication especially in countries with limited resources, where duodenal biopsy is not so easily performed.